Patients with dMMR/MSI-H resectable gastroesophageal adenocarcinoma have a relatively favorable prognosis and limited benefit from an older chemotherapy regimen. Recent trials showed that neoadjuvant ...
Please provide your email address to receive an email when new articles are posted on . FLOT protocol conferred longer OS at multiple endpoints compared with CROSS in patients with advanced esophageal ...
The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...
Perioperative FLOT vs EOX regimen and non-metastatic gastric carcinoma survival outcomes: Real-world data from a tertiary cancer centre, India. This is an ASCO Meeting Abstract from the 2025 ASCO ...
CHICAGO -- A perioperative regimen of four cycles of chemotherapy before and after surgery extended overall survival (OS) compared with neoadjuvant chemoradiation in patients with locally-advanced, ...
Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs.
Moderated by Dr Maurie Markman, the panel included Dr Kevin Kalinsky from Emory University, Dr Michael Cecchini from Yale Cancer Center, and Dr Jacob Sands from Dana-Farber Cancer Institute. The ...
EU recommends approval of AstraZeneca’s Imfinzi perioperative regimen for patients with early gastric and gastroesophageal cancers ...
The FDA approved Imfinzi with FLOT chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma, based on the MATTERHORN trial results. The MATTERHORN trial demonstrated improved ...
Perioperative chemotherapy with chemotherapy led to improved survival outcomes versus neoadjuvant chemoradiation in resectable esophageal cancer. Perioperative chemotherapy (treatment around the time ...
Recommendation based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results